Implantable cardioverter-defibrillator therapy is indicated in all patients with ischaemic cardiomyopathy and severe systolic dysfunction: pro

14 April 2026 (13:15 - 13:25)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Professor Christian Sticherling

University Hospital Basel, Basel (Switzerland)

5 More presentations in this session

Presentation thumbnail

Implantable cardioverter-defibrillator therapy is indicated in all patients with ischaemic cardiomyopathy and severe systolic dysfunction: con

Doctor N. Dagres (Berlin, DE)

Presentation thumbnail

Implantable cardioverter-defibrillator therapy is indicated in all patients with ischaemic cardiomyopathy and severe systolic dysfunction: discussion

Presentation thumbnail

The left bundle branch pacing-shock lead will become standard in implantable cardioverter-defibrillator therapy: pro

Doctor J. Karvonen (Helsinki, FI)

Presentation thumbnail

The left bundle branch pacing-shock lead will become standard in implantable cardioverter-defibrillator therapy: con

Associate Professor G. Upadhyay (Chicago, US)

Presentation thumbnail

The left bundle branch pacing-shock lead will become standard in implantable cardioverter-defibrillator therapy: discussion

Access the full session

Session thumbnail

Debate on cardiac implantable electronic device therapy

The Event

Event poster

EHRA 2026

14 April 2026 13:15 CET

You may be interested in

Congress Presentation

Limitations of current ICD indications in ischemic cardiomyopathy

Congress Presentation

Implantable cardioverter-defibrillator therapy is indicated in all patients with ischaemic cardiomyopathy and severe systolic dysfunction: con

Congress Presentation

Implantable cardioverter-defibrillator therapy is indicated in all patients with ischaemic cardiomyopathy and severe systolic dysfunction: discussion

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources